 |  Sirnaomics, Inc. is a biopharmaceutical company discovering and
developing novel targeted therapeutics for critical human diseases by using RNA
interference (RNAi) technology. The company was founded in early 2007 with the
mission of advancing RNAi technology using multi-targeted design of small
interfering RNA (siRNA) and nanoparticle-enhanced delivery.
The name of the company
Sirnaomics (/ser-'now-miks/) is derived from the molecular
terminology "siRNA" with the suffix "-omics"
to signify the bridge between the study of the structure and function of small
interfering RNAs (including their gene silencing properties) and the molecular
comprehension of the complex interplay between genes these molecules target and
pathways implicated in disease. Read more... | |
| Keyword: |  |
|
|
| |
| |||
STP601 (Acurita) -siRNA Therapeutics for AMD and Retinopathy
STP705 (Cutasil®) - siRNA Therapeutics for Skin Scarless Wound Healing
According to The Mattson Jack Group, an independent research group, the US commercial market for reduction of scarring in the skin is valued at approximately US$4 billion a year. There are some 42 million patients each year who could potentially benefit from pharmaceuticals that prevent or reduce scarring in the skin. There are 41.8 million surgical procedures to the skin each year in Europe and 70 million procedures annually in the United States involving wounds, which could benefit from a drug that improves the appearance of the scar. Currently there are no related pharmaceuticals available in the market either in the US or Europe.null
RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications along with aiding in the basic research. It has been found that, various components, such as siRNA & miRNA possess immense opportunities and provides a wide range in different drug classes. Besides, these molecules find wide applications in various sectors, such as functional genomics, disease diagnostics, and agriculture, among others. Many studies indicate that the usage of siRNA and miRNA in industries and academic institutions will witness ... Read more
STP702 (FluQuit) -
siRNA Therapeutics
against Influenza Infection
Our patented siRNA therapeutics shown to have efficacy against H5N1 (avian flu) have also
demonstrated inhibitory activity against H1N1 (swine flu). With the recent
pandemic of H1N1 the market for vaccines and therapeutics has increased
dramatically in to $billions. With the rapid mutation rate of the flu virus we
are seeing resistance to drugs such as amantadine and even tamiflu. Sirnaomics
has licensed IP describing siRNA sequences for use in a therapeutic cocktail
against flu and has identified a vehicle for administration of these siRNAs to
the lung.
STP503 (Trisilensa) -